{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:36:22Z","timestamp":1792506982404,"version":"4.5.0"},"reference-count":76,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the proliferation of immature lymphoid cells. Despite advances in chemotherapy, a significant proportion of patients continue to have poor outcomes. Immunotherapy has emerged as a transformative approach in the treatment of ALL, offering new hope for these patients. This advances viewpoint article provides a comprehensive overview of the role of immunotherapy in ALL, focusing on the mechanisms of action, the timing of its use, the patient populations most likely to benefit, and drug resistance. We discussed the major immunotherapeutic modalities, including monoclonal antibodies, bispecific T-cell engagers, and chimeric antigen receptor T-cell therapy. We review key clinical trials that have shaped the current landscape of immunotherapy in B-cell precursor (BCP)\u2013ALL, along with future directions in this rapidly evolving field and discussed our perspective on how best to exploit the use of immunotherapy for patients with newly diagnosed adult BCP-ALL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025015936","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T19:23:41Z","timestamp":1760988221000},"page":"999-1011","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Immunotherapy in the up-front treatment of adult B-cell precursor acute lymphoblastic leukemia: when, how, who?"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1075-2988","authenticated-orcid":false,"given":"Soumyadeep","family":"Datta","sequence":"first","affiliation":[{"name":"1Department of Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"3","key":"2026022411365541700_bib1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","article-title":"A 50-year journey to cure childhood acute lymphoblastic leukemia","volume":"50","author":"Pui","year":"2013","journal-title":"Semin Hematol"},{"issue":"9","key":"2026022411365541700_bib2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"2026022411365541700_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","article-title":"The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades","volume":"16","author":"Jabbour","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2026022411365541700_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.23.00546","article-title":"Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL","volume":"42","author":"Stelljes","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026022411365541700_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"2026022411365541700_bib6","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"2026022411365541700_bib7","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2026022411365541700_bib8","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1016\/S2352-3026(22)00285-X","article-title":"Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial","volume":"9","author":"Jabbour","year":"2022","journal-title":"Lancet Haematol"},{"issue":"21","key":"2026022411365541700_bib9","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1182\/blood.2024027500","article-title":"Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study","volume":"145","author":"Bassan","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2026022411365541700_bib10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"issue":"14","key":"2026022411365541700_bib11","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.21.01766","article-title":"SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"40","author":"Advani","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026022411365541700_bib12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/ajh.27227","article-title":"Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"issue":"16","key":"2026022411365541700_bib13","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II single-arm, multicenter study (ALCANTARA)","volume":"35","author":"Martinelli","year":"2017","journal-title":"J Clin Oncol"},{"issue":"17","key":"2026022411365541700_bib14","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"2026022411365541700_bib15","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Fo\u00e0","year":"2024","journal-title":"J Clin Oncol"},{"issue":"36","key":"2026022411365541700_bib16","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.24.00272","article-title":"Results of the simultaneous combination of ponatinib and blinatumomab in Philadelphia chromosome-positive ALL","volume":"42","author":"Kantarjian","year":"2024","journal-title":"JCO"},{"issue":"suppl 1","key":"2026022411365541700_bib17","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood-2024-207892","article-title":"Efficacy and toxicity of frontline ponatinib plus blinatumomab for adult Ph+ ALL patients of all ages. Intermediate analysis of the Gimema ALL2820","volume":"144","author":"Chiaretti","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2026022411365541700_bib18","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/bloodadvances.2024014986","article-title":"TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALL","volume":"9","author":"Aldoss","year":"2025","journal-title":"Blood Adv"},{"issue":"10","key":"2026022411365541700_bib19","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2026022411365541700_bib20","doi-asserted-by":"crossref","first-page":"8985","DOI":"10.1182\/blood-2022-170279","article-title":"Interim results of a phase 1\/2 study of pembrolizumab combined with blinatumomab in patients with relapsed\/refractory (r\/r) ALL","volume":"140","author":"Sandhu","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2026022411365541700_bib21","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1182\/blood-2023-191109","article-title":"Blinatumomab in combination with immune checkpoint inhibitors (ICIs) of PD-1 and CTLA-4 in adult patients with relapsed\/refractory (R\/R) CD19 positive B-cell acute lymphoblastic leukemia (ALL): results of a phase I study","volume":"142","author":"Webster","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2026022411365541700_bib22","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/pbc.25953","article-title":"Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy","volume":"63","author":"Rayes","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2026022411365541700_bib23","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/hematology.2019000018","article-title":"Mechanisms of and approaches to overcoming resistance to immunotherapy","volume":"2019","author":"Schultz","year":"2019","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"suppl","key":"2026022411365541700_bib24","doi-asserted-by":"crossref","first-page":"e1944062","DOI":"10.1097\/01.HS9.0000967372.19440.62","article-title":"Consolidation with blinatumomab improves overall and relapse-free survival in patients with newly diagnosed B-cell acute lymphoblastic leukemia: impact of age and MRD level in ECOG-ACRIN E1910","volume":"7","author":"Litzow MR","year":"2023","journal-title":"Hemasphere"},{"issue":"14","key":"2026022411365541700_bib25","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/cncr.30031","article-title":"Blinatumomab treatment of older adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies","volume":"122","author":"Kantarjian","year":"2016","journal-title":"Cancer"},{"issue":"36","key":"2026022411365541700_bib26","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026022411365541700_bib27","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood-2021-146163","article-title":"Frontline consolidation with blinatumomab for high-risk Philadelphia-negative acute lymphoblastic adult patients. early results from the GRAALL-2014-QUEST phase 2","volume":"138","author":"Boissel","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2026022411365541700_bib28","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1182\/blood-2021-151826","article-title":"Sequential blinatumomab with reduced intensity chemotherapy in the treatment of older adults with newly diagnosed Ph negative B-precursor acute lymphoblastic leukemia- interim analysis of the Australasian Leukemia and Lymphoma Group ALL08 Study","volume":"138","author":"Fleming","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2026022411365541700_bib29","doi-asserted-by":"crossref","first-page":"6134","DOI":"10.1182\/blood-2022-156080","article-title":"Blinatumomab alternating with low-intensity chemotherapy (CT) treatment for older adults with newly diagnosed Philadelphia (Ph)-negative B-cell precursor acute lymphoblastic leukemia (BCPALL) is well tolerated and efficacious: safety run-in results for the phase 3 randomized controlled Golden Gate Study","volume":"140","author":"Jabbour","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2026022411365541700_bib30","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1182\/blood-2021-146214","article-title":"Dose-reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with B-precursor adult lymphoblastic leukemia (ALL): results of the ongoing GMALL bold trial","volume":"138","author":"Goekbuget","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2026022411365541700_bib31","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/bloodadvances.2022008216","article-title":"Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in Ph+ acute lymphoblastic leukemia","volume":"7","author":"Advani","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2026022411365541700_bib32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.2024025800","article-title":"Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia","volume":"145","author":"Luskin","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2026022411365541700_bib33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"issue":"8","key":"2026022411365541700_bib34","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026022411365541700_bib35","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1182\/blood-2022-157937","article-title":"GIMEMA ALL2418: interim analysis of a phase IIa study of feasibility and effectiveness of inotuzumab ozogamicin in adult patients with B-cell acute lymphoblastic leukemia with positive minimal residual disease before any hematopoietic stem cell transplantation [abstract]","volume":"140","author":"Marconi","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2026022411365541700_bib36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.2023022330","article-title":"Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission","volume":"143","author":"Jabbour","year":"2024","journal-title":"Blood"},{"issue":"36","key":"2026022411365541700_bib37","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1200\/JCO.24.00490","article-title":"Inotuzumab ozogamicin and low-intensity chemotherapy in older patients with newly diagnosed CD22+ Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"42","author":"Chevallier","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026022411365541700_bib38","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2026022411365541700_bib39","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood-2024-209438","article-title":"Addition of inotuzumab to a pediatric inspired chemotherapy regimen in young adult patients with B-cell acute lymphoblastic leukemia: findings from the Alliance A041501 phase 3 randomized trial","volume":"144","author":"DeAngelo","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026022411365541700_bib40","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2021-149478","article-title":"A phase 3 randomized trial of inotuzumab ozogamicin for newly diagnosed high-risk B-ALL: safety phase results from Children's Oncology Group Protocol AALL1732 [abstract]","volume":"138","author":"McNeer","year":"2021","journal-title":"Blood"},{"issue":"16 suppl","key":"2026022411365541700_bib41","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/JCO.2023.41.16_suppl.7006","article-title":"Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703","volume":"41","author":"Wieduwilt","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026022411365541700_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1158\/2643-3230.BCD-21-0087","article-title":"Modulation of CD22 protein expression in childhood leukemia by pervasive splicing aberrations: implications for CD22-directed immunotherapies","volume":"3","author":"Zheng","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2026022411365541700_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/bjh.16949","article-title":"Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia","volume":"191","author":"Ryland","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"2026022411365541700_bib44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2024023930","article-title":"Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL","volume":"144","author":"Zhao","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026022411365541700_bib45","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/bloodadvances.2021006810","article-title":"CD22low\/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed\/refractory acute lymphoblastic leukemia","volume":"7","author":"Wintering","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"2026022411365541700_bib46","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood.2024026085","article-title":"DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia","volume":"145","author":"Escherich","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2026022411365541700_bib47","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood.2024028215","article-title":"Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin","volume":"146","author":"Escherich","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2026022411365541700_bib48","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ajh.27576","article-title":"Hyper-CVAD and sequential blinatumomab without and with inotuzumab in young adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","volume":"100","author":"Kantarjian","year":"2025","journal-title":"Am J Hematol"},{"issue":"5","key":"2026022411365541700_bib49","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"10299","key":"2026022411365541700_bib50","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"2026022411365541700_bib51","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"2026022411365541700_bib52","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026022411365541700_bib53","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1182\/blood-2019-126429","article-title":"Anti-CD19\/CD22 dual CAR-T therapy for refractory and relapsed B-cell acute lymphoblastic leukemia","volume":"134","author":"Yang","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2026022411365541700_bib54","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2024-204200","article-title":"Safety and efficacy of bicistronic CD19\/CD22 CAR T cell therapy in childhood B cell acute lymphoblastic leukemia","volume":"144","author":"Wan","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2026022411365541700_bib55","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a Pediatric Real-World Chimeric Antigen Receptor Consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026022411365541700_bib56","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2026022411365541700_bib57","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"9","key":"2026022411365541700_bib58","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","article-title":"Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines","volume":"19","author":"Brown","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"2026022411365541700_bib59","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"G\u00f6kbuget","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2026022411365541700_bib60","first-page":"233","article-title":"Management of hepatic sinusoidal obstruction syndrome following inotuzumab ozogamicin treatment in patients with acute lymphoblastic leukemia","volume":"24","author":"Kebriaei","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"2026022411365541700_bib61","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/ajh.27637","article-title":"Five-year real-world safety of inotuzumab ozogamicin before hematopoietic stem cell transplantation in B-cell precursor acute lymphoblastic leukemia","volume":"100","author":"de Lima","year":"2025","journal-title":"Am J Hematol"},{"issue":"5","key":"2026022411365541700_bib62","first-page":"1294","article-title":"Safety and preliminary efficacy of inotuzumab ozogamicin combined with low-intensity chemotherapy","volume":"105","author":"DiNardo","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"2026022411365541700_bib63","first-page":"1001","article-title":"Inotuzumab ozogamicin in combination with chemotherapy for newly diagnosed Philadelphia chromosome-negative B-cell ALL","volume":"127","author":"Jabbour","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"2026022411365541700_bib64","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2026022411365541700_bib65","doi-asserted-by":"crossref","first-page":"101485","DOI":"10.1016\/j.beha.2023.101485","article-title":"The current landscape: allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia","volume":"36","author":"Prockop","year":"2023","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"2026022411365541700_bib66","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/bloodadvances.2018027003","article-title":"The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia","volume":"3","author":"Yeshurun","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"2026022411365541700_bib67","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bmt.1703808","article-title":"Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival","volume":"31","author":"Gustafsson Jernberg","year":"2003","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"2026022411365541700_bib68","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/sj.leu.2402690","article-title":"Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors","volume":"16","author":"Locatelli","year":"2002","journal-title":"Leukemia"},{"issue":"25","key":"2026022411365541700_bib69","doi-asserted-by":"crossref","first-page":"6683","DOI":"10.1182\/blood-2011-05-354233","article-title":"No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission","volume":"118","author":"Dini","year":"2011","journal-title":"Blood"},{"issue":"22","key":"2026022411365541700_bib70","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","article-title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients","volume":"125","author":"Pulsipher","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2026022411365541700_bib71","doi-asserted-by":"crossref","first-page":"101414","DOI":"10.1016\/j.beha.2022.101414","article-title":"Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant?","volume":"35","author":"Marinos","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"2026022411365541700_bib72","first-page":"1105","article-title":"Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"110","author":"Aldoss","year":"2025","journal-title":"Haematologica"},{"issue":"6","key":"2026022411365541700_bib73","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2026022411365541700_bib74","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.13792","article-title":"Current status of chimeric antigen receptor therapy for haematological malignancies","volume":"172","author":"Maude","year":"2016","journal-title":"Br J Haematol"},{"issue":"16","key":"2026022411365541700_bib75","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"27","key":"2026022411365541700_bib76","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/999\/2502863\/blooda_adv-2025-015936-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/999\/2502863\/blooda_adv-2025-015936-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:37:12Z","timestamp":1771951032000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/4\/999\/547847\/Immunotherapy-in-the-up-front-treatment-of-adult-B"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025015936","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,24]]},"published":{"date-parts":[[2026,2,11]]}}}